Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Contact Us for the Latest Status
Closed for Enrollment
-
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) (PROSPERO)
Rochester, Minn.
The purpose of this study is to evaluate the long-term effect of tozorakimab as an add on to standard of care (SoC) compared with SoC plus placebo on the time to first severe chronic obstructive pulmonary disease (COPD) exacerbation in former smokers.
-
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation (BOREAS)
Rochester, Minn.
The primary purpose of this study is to evaluate the effectiveness of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by - Annualized rate of acute moderate and severe COPD exacerbation (AECOPD).
-
Beta-Blocker Use in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Acute Myocardial Infarction (an Ancillary Study to Beta-Blockers for the Prevention of Acute Exacerbations of COPD) (BLOCK 2)
Rochester, Minn.
The purpose of this study is to determine the prevalence of COPD in patients admitted to the hospital with an acute myocardial infarction (AMI) and to characterize the phenotypic expression and severity of their underlying lung disease. Also to determine the association between beta-blocker use at discharge and cardiopulmonary outcomes in patients with COPD and AMI.
-
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home - a Multi-center Randomized Controlled Trial
Rochester, Minn.
The purpose of this study is to determine if myAirvo 3 use increases the time to first moderate exacerbation/severe exacerbation (hospitalization)/all-cause mortality in patients with moderate to very severe COPD. [ Time Frame: 1 year ]
.